PURPOSE OF THE STUDY: Defibrotide, an orally bioavailable polydisperse oligonucleotide, has promising activity in hepatic veno-occlusive disease, a stem cell transplantation-related toxicity characterized by microangiopathy. The antithrombotic properties of defibrotide and its minimal hemorrhagic risk could serve for treatment of cancer-associated thrombotic complications. Given its cytoprotective effect on endothelium, we investigated whether defibrotide protects tumor cells from cytotoxic antitumor agents. Further, given its antiadhesive properties, we evaluated whether defibrotide modulates the protection conferred to multiple myeloma cells by bone marrow stromal cells. METHODS- RESULTS: Defibrotide lacks significant single-agent in vitro cytotoxicity on multiple myeloma or solid tumor cells and does not attenuate their in vitro response to dexamethasone, bortezomib, immunomodulatory thalidomide derivatives, and conventional chemotherapeutics, including melphalan and cyclophosphamide. Importantly, defibrotide enhances in vivo chemosensitivity of multiple myeloma and mammary carcinoma xenografts in animal models. In cocultures of multiple myeloma cells with bone marrow stromal cells in vitro, defibrotide enhances the multiple myeloma cell sensitivity to melphalan and dexamethasone, and decreases multiple myeloma-bone marrow stromal cell adhesion and its sequelae, including nuclear factor-kappaB activation in multiple myeloma and bone marrow stromal cells, and associated cytokine production. Moreover, defibrotide inhibits expression and/or function of key mediators of multiple myeloma interaction with bone marrow stromal cell and endothelium, including heparanase, angiogenic cytokines, and adhesion molecules. CONCLUSION: Defibrotide's in vivo chemosensitizing properties and lack of direct in vitro activity against tumor cells suggest that it favorably modulates antitumor interactions between bone marrow stromal cells and endothelia in the tumor microenvironment. These data support clinical studies of defibrotide in combination with conventional and novel therapies to potentially improve patient outcome in multiple myeloma and other malignancies.
PURPOSE OF THE STUDY: Defibrotide, an orally bioavailable polydisperse oligonucleotide, has promising activity in hepatic veno-occlusive disease, a stem cell transplantation-related toxicity characterized by microangiopathy. The antithrombotic properties of defibrotide and its minimal hemorrhagic risk could serve for treatment of cancer-associated thrombotic complications. Given its cytoprotective effect on endothelium, we investigated whether defibrotide protects tumor cells from cytotoxic antitumor agents. Further, given its antiadhesive properties, we evaluated whether defibrotide modulates the protection conferred to multiple myeloma cells by bone marrow stromal cells. METHODS- RESULTS:Defibrotide lacks significant single-agent in vitro cytotoxicity on multiple myeloma or solid tumor cells and does not attenuate their in vitro response to dexamethasone, bortezomib, immunomodulatory thalidomide derivatives, and conventional chemotherapeutics, including melphalan and cyclophosphamide. Importantly, defibrotide enhances in vivo chemosensitivity of multiple myeloma and mammary carcinoma xenografts in animal models. In cocultures of multiple myeloma cells with bone marrow stromal cells in vitro, defibrotide enhances the multiple myeloma cell sensitivity to melphalan and dexamethasone, and decreases multiple myeloma-bone marrow stromal cell adhesion and its sequelae, including nuclear factor-kappaB activation in multiple myeloma and bone marrow stromal cells, and associated cytokine production. Moreover, defibrotide inhibits expression and/or function of key mediators of multiple myeloma interaction with bone marrow stromal cell and endothelium, including heparanase, angiogenic cytokines, and adhesion molecules. CONCLUSION:Defibrotide's in vivo chemosensitizing properties and lack of direct in vitro activity against tumor cells suggest that it favorably modulates antitumor interactions between bone marrow stromal cells and endothelia in the tumor microenvironment. These data support clinical studies of defibrotide in combination with conventional and novel therapies to potentially improve patient outcome in multiple myeloma and other malignancies.
Authors: R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui Journal: Br J Haematol Date: 2000-12 Impact factor: 6.998
Authors: D Gupta; S P Treon; Y Shima; T Hideshima; K Podar; Y T Tai; B Lin; S Lentzsch; F E Davies; D Chauhan; R L Schlossman; P Richardson; P Ralph; L Wu; F Payvandi; G Muller; D I Stirling; K C Anderson Journal: Leukemia Date: 2001-12 Impact factor: 11.528
Authors: Carmelo Carlo-Stella; Massimo Di Nicola; Michele Magni; Paolo Longoni; Marco Milanesi; Claudio Stucchi; Loredana Cleris; Franca Formelli; Massimo A Gianni Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: J Bogdanos; D Karamanolakis; R Tenta; A Tsintavis; C Milathianakis; C Mitsiades; M Koutsilieris Journal: Endocr Relat Cancer Date: 2003-06 Impact factor: 5.678
Authors: Christopher Strouse; Paul Richardson; Grant Prentice; Sandra Korman; Robin Hume; Bijan Nejadnik; Mary M Horowitz; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2016-04-19 Impact factor: 5.742
Authors: Joseph P Ritchie; Vishnu C Ramani; Yongsheng Ren; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Sergio Penco; Claudio Pisano; Paolo Carminati; Monica Tortoreto; Franco Zunino; Israel Vlodavsky; Ralph D Sanderson; Yang Yang Journal: Clin Cancer Res Date: 2011-01-21 Impact factor: 12.531
Authors: Paul G Richardson; Vincent T Ho; Sergio Giralt; Sally Arai; Shin Mineishi; Corey Cutler; Joseph H Antin; Nicole Stavitzski; Dietger Niederwieser; Ernst Holler; Enric Carreras; Robert Soiffer Journal: Ther Adv Hematol Date: 2012-08